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Abstract 
A major question about he pathogenesis of myotonic dystrophy (DM) is how the (CTG), repeat mutation alters expression ofthe DM 
gene and how that is related to disease causation. Most previous tudies have found a decrease inDM RNA and protein in patient tissue. 
In contrast to these reports we find, unexpectedly, that independent of the size of the CTG repeat: (1) there are equal levels of RNA 
products of mutant and normal alleles, and (2) levels of Mt-PK in skeletal muscle from DM patients i  unaltered from normal. These 
findings are consistent with the recent hypothesis that mutant DM DNA or RNA may cause disease by disrupting the function of other, 
yet unidentified, genes. 
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Myotonic dystrophy (DM) is an autosomal dominant 
human genetic disease with multisystem effects including 
muscle weakness and myotonia [1]. The molecular basis of 
DM is now known to be the amplification of a trinucleo- 
tide repeat (CTG) n situated in the 3' non-coding exon of a 
gene which encodes a putative serine-threonine protein 
kinase named myotonin protein kinase (Mt-PK) [2-4]. The 
cellular effects of the (CTG), expansion and how they lead 
to symptomatology are unknown. Since the CTG expan- 
sion is not translated into a protein product, previous 
studies have attempted to correlate the DM phenotype to 
changes in the levels of DM RNA or protein (DM-PK) in 
DM affected tissues. Studies on RNA levels in muscle 
from DM patients have, however, reported conflicting 
results finding either a decrease in mRNA product of the 
abnormal allele [5,7,8], or normal allele [6] or in contrast, 
in congenital DM, a marked increase in mutant mRNA [9] 
levels. Most studies of the level of Mt-PK in DM skeletal 
muscle have found a decrease (up to 40%) [8,10]. 
Since accurate determination of the level of transcrip- 
tion and translation of the DM gene in DM affected tissues 
is crucial to understanding the pathogenesis of DM, we 
analyzed the steady state levels of DM RNA products of 
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mutant and normal alleles and levels of Mt-PK in affected 
skeletal muscle from adult DM patients. Also, as the 
severity of disease has been directly correlated with the 
length of the CTG repeat we specifically asked whether 
there was any correlation between the length of the CTG 
repeat and the level of expression of the DM gene in 
affected tissue. 
Skeletal muscle biopsy samples from adult DM patients 
were analyzed as described [9] for the size of the CTG 
repeat. Three samples from patients of adult DM with 
repeat size varying from 450 to 900 repeats were selected 
for further analysis. To distinguish between normal and 
mutant alleles we took advantage of a Bpml exon 10 
polymorphism [9]. RNA levels were assessed using a 
reverse transcriptase-polymerase chain reaction assay. 
Primers were chosen from different exons (to allow identi- 
fication of spliced RNA) [11] to reverse transcribe RNA 
extracted from skeletal muscle samples and to then am- 
plify a region which spans the Bpml site. Bpml digestion 
of the amplified DNA allowed separation of normal (178 
bp) and mutant (133 bp) alleles. No difference was found 
in the levels of RNA product between ormal and abnor- 
mal alleles (Fig. 1). Band intensity comparisons were 
made between normal and mutant alleles in the same 
sample with the normal allele (178 bp) serving as an 
internal control for the mutant allele (133 bp). Interestingly 
even the patient with a very long repeat (900 repeats) and 
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Fig. 1. Reverse transcriptase-polymerase ch inreaction assay for steady state levels of spliced DM-mRNA in skeletal muscle from DM patients and a 
normal individual. PCR printers (5'-CTGTCGGACATTCGGAAGGT-3' and 5'-CATCCTGTGGGGACACCGAG-3') were used to amplify a 178 bp 
fragment spanning the site for the Bpml exon polymorphism and an aliquot was digested with Bpml. Undigested and digested samples have been run on 
adjacent lanes. Lanes 1,2: Normal skeletal muscle (SKM), age 30 yr; lanes 3,4: DM SKM, age 29 yr, 450 repeats; lanes 5,6: DM SKM, age 22 yr, 700 
repeats; lanes 7,8: DM SKM, age 26 yr, 900 repeats. Bpml restriction digestion of the abnormal lele yields a 133 bp and 45 bp fragments [11]. Equal 
levels of RNA products of routant (133 bp) and normal alleles (178 bp) are seen, independent of he size of the CTG repeat on an ethidium bromide stained 
3% agarose gel. Negatives ofgel pictures were scanned with a LKB densitometer and in each sample the mutant allele was compared tothe normal allele. 
severe clinical symptoms howed no decrease in the level 
of transcription from the mutant allele. 
Equal transcription from normal and mutant alleles does 
not exclude the possibility of equivalent decreases or 
increases in expression from both alleles. We therefore 
looked next at levels of Mt-PK in skeletal muscle from a 
normal individual and compared them to levels in the same 
three DM patients with CTG repeats ranging from 450 to 
900. Recently an antibody has been obtained which recog- 
nizes the full length Mt-PK [12]. Immunoblotting with this 
antibody which was raised to a synthetic peptide from the 
kinase domain of the Mt-PK consistently detected my- 
otonin protein kinase as a single band 72 kilodaltons in 
size. The 72 kDa DM protein, which represents the full 
length MtPK isoform [10,12], was present in equal amounts 
in normal and DM skeletal muscle (Fig. 2). 
Most studies of adult DM have reported decreases in 
the level of processed DM RNA in DM muscle (which is 
thought o be due to impaired RNA processing) [11,13,14], 
and also reported ecreases in levels of Mt-PK in affected 
DM skeletal muscle [8,10]. These alterations have been 
considered important in the pathogenesis of the DM phe- 
notype and consider abnormalities of Mt-PK to be central 
to the causation of DM. Some of the previous studies to 
quantitate RNA levels using RT-PCR have not, however, 
fully considered inefficient action of Taq polymerase and 
especially reverse transcriptase through the expanded CG 
rich repeat region. To avoid these inaccuracies we used a 
DM gene specific primer [11] located 5' of the repeat 
region for reverse transcription so that the region analyzed 
did not include the repeat region. Using this approach we 
find that the levels of RNA products of normal and mutant 
alleles are equal. We also find that equal levels of Mt-PK 
protein can be detected by Western blot analysis in muscle 
from a normal individual and three DM patients. The CTG 
repeats in the DM patients we had selected varied from 
450 to 900. However no difference in the level of Mt-PK 
was found. To the best of our knowledge this is the first 
demonstration that the expression of normal sized Mt-PK, 
even in severely affected DM muscle, is unchanged from 
normal. Our findings are in variance with what has been 
previously reported but inaccuracies in protein estimation 
can occur due to variations in the extent of muscle fibrosis, 
tissue preparation and time to freezing and difficulties in 
accurate quantitation of total protein [15]. Alternatively it 
can be speculated that the difference between our findings 
and previous reports may have resulted from the analysis 
of different subsets of DM patients with varying amounts 
of Mt-PK in each group. Studies of larger number of DM 
patients will be needed to clarify this issue. 
The finding that skeletal muscle from adult DM patients 
have normal levels of Mt-PK raises some interesting and 
important questions about the pathogenesis of this complex 
disease. Since the DM mutation is located in the 3'-UTR 
region of the DM gene, alteration of Mt-PK function or 
toxic alterations of the protein secondary to changes in 
protein sequence or structure are unlikely. Normal levels 
of Mt-PK in affected muscle tissue, therefore suggests that 
the abnormal phenotype may not be caused solely by an 
alteration of the DM gene product, myotonin protein ki- 
nase. The recent findings that knockout mice without any 
Mt-PK and transgenic animals which overexpress the DM 
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tively normal could affect muscle cell differentiation by 
sequestering proteins that regulate differentiation [18] or 
are important in RNA processing. CTG expansion muta- 
tion causing such a gain of function, would be consistent 
with the autosomal dominant inheritance seen in myotonic 
dystrophy. 
This work was supported by a NIH (NINDS) research 
grant to S.B. We thank Dr C.S. Rao for providing tissue 
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Fig. 2. Immunoblot analysis of DM and normal samples using an 
antibody to Mt-protein kinase [12]. Top panel, Lane 1, normal skeletal 
muscle (SKM); lane 2, DM,SKM (450 repeats); lane 3, DM SKM (700 
repeats); lane 4, DM SKM (900 repeats). Equal levels of the 72 kDa 
Mt-PK are seen in all normal and DM samples. Band intensities were 
quantified with a LKB laser densitometer and the relative value for the 
amount of DMPK was determined by normalization to the level of actin. 
Similar results were obtained in three independent experiments. Bottom 
panel: silver-stained polyacrylamide gel loaded with 15 /xg of protein 
from each of the above samples (lane numbers correspond to samples in 
top panel). 
gene [16] do not exhibit any abnormal phenotype is consis- 
tent with this hypothesis. The findings reported here are 
also consistent with and direct attention to the recently 
proposed hypothesis [17] that the DM mutation may result 
in disease by disrupting the function of other, still uniden- 
tified, genes. 
Alteration of function of another gene may be sec- 
ondary to altered transcription of an adjacent gene due to 
alterations in chromatin topology [17]. Recently a large 
homeodomain encoding ene has been identified in close 
proximity to the CTG repeat [17] although no abnormali- 
ties in the expression of this gene in DM tissue have yet 
been reported. Alternatively the amplified CTG repeat in 
mutant DM DNA could titrate out tissue specific DNA 
binding proteins or mutant DM RNA, although quantita- 
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